Multiple Myeloma
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
Conference Coverage
Debate: Should CAR T Best Be Used in Early MM Relapse?
When patients with myeloma relapse, blood cancer specialists disagree on whether and when to treat them with CAR T-cell therapy.
Conference Coverage
A Simple Blood Test May Predict Cancer Risk in T2D
Can the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-alpha), and high-sensitivity C-reactive protein (hsCRP) be predictive...
Feature
Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?
Researchers analyzed whole genome sequencing data from 10,866 women in the WHI to explore possible associations between CHIP, mCA, and solid...
From the Journals
Teclistamab Promising as a Treatment of Last Resort for Refractory Autoimmune Diseases
In small studies, teclistamab significantly improved autoimmune disease activity and demonstrated a good safety profile.
Sponsored Supplement
Activating the Immune System to Treat Multiple Myeloma
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Commentary
Multiple Myeloma: New Treatments Aid Patient Subgroups
A leading Spanish blood cancer expert discusses the striking benefits of innovative new therapies for multiple myeloma.
Feature
When Childhood Cancer Survivors Face Sexual Challenges
The disruptions caused by cancer and its treatment can interfere with normal physiological and psychological development, leading to issues with...
News
FDA Issues Complete Response Letter for Myeloma Drug
FDA declines to approve linvoseltamab for treatment of relapsed/refractory multiple myeloma, citing issues at a third-party manufacturer.
News
FDA Approves Axatilimab for Chronic GVHD
For children and adults with graft versus host disease, a first-in-class monoclonal antibody axatilimab has received FDA approval.
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.